WO1999055686A2 - Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds - Google Patents
Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds Download PDFInfo
- Publication number
- WO1999055686A2 WO1999055686A2 PCT/EP1999/002456 EP9902456W WO9955686A2 WO 1999055686 A2 WO1999055686 A2 WO 1999055686A2 EP 9902456 W EP9902456 W EP 9902456W WO 9955686 A2 WO9955686 A2 WO 9955686A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- naphthylamine
- acid catalyst
- process according
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C249/02—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of compounds containing imino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the instant invention pertains to a novel process for preparing 4-(phenyl, 3-chlorophenyl, 4- chlorophenyl or 3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1 -ylidene-alkylamine from ⁇ - tetralone.
- Tetralones are known for being particularly useful as synthesis intermediates for preparing different serotonin pre-synaptic inhibitor compounds with antidepressant activity. This is described more precisely in United States Patent Nos. 4,029,731 and 4,045,488 and European Patent No. 30,081. Until now, the 4-aryltetralones have been prepared using a method comprising five steps described by Johnson and Daub in Organic Reactions, Vol. VI, pages 1 -73 and in European Patent No. 30,081.
- This method involves (a) the reaction of benzoyl chloride with an aromatic hydrocarbon in the presence of aluminum chloride to form a benzophenone; (b) condensation of said benzophenone under the conditions of the Stobbe reaction in the presence of a strong base, such as potassium tert-butoxide, with diethyl succinate; (c) decarboxylation of the product obtained using an aqueous hydrobromic acid solution to form a 4,4-diarylbutenoic acid; (d) hydrogenation of said acid on palladium/charcoal to form the corresponding 4,4-diarylbutanoic acid; and (e) cyclization of the butanoic acid into a 4-aryltetralone either directly by means of hydrofluoric acid or polyphosphoric acid, or, after transformation into the corresponding acid chloride using thionyl chloride, by the action of aluminum chloride under the conditions of the Friedel-Crafts reaction.
- a strong base such as potassium tert-butoxide
- the instant process provides a method of going directly to the desired imine intermediate.
- the instant invention relates to a new process for the preparation of a compound of formula
- R is alkyl of 1 to 6 carbon atoms
- R, and R 2 are independently hydrogen or chloro, which comprises reacting N-alkyl-1 -naphthylamine of formula (ll)
- R is methyl or ethyl, and R, and R 2 are both chloro.
- R is methyl
- the present invention refers to a process for preparing the pharmaceutical intermediate of formula (I) from N-alkyl-1 -naphthylamine according to the following scheme:
- R is alkyl of 1 to 6 carbon atoms
- R, and R 2 are independently hydrogen or chloro, in the presence of an effective amount of an acid catalyst to form the compound of formula (I).
- the pharmaceutical intermediate is 4-(phenyl, 3-chlorophenyl, 4-chlorophenyl or 3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-ylidene-alkylamine.
- reaction step is carried out in the
- reaction step is preferably carried out with 5% of a Pd/C catalyst.
- the instant process refers to the preparation of 4-(3,4-dichlorophenyl)-3,4- dihydro-2H-naphthalen-1-ylidene-methylamine of formula
- the acid catalyst is aluminum bromide or aluminum chloride, most preferably aluminum chloride.
- the amount of acid catalyst used is from one molar equivalent to six molar equivalents based on the N-alkyl-1 -naphthylamine, preferably N-methyl-1 -naphthylamine.
- the reaction is carried with aluminum bromide or aluminum chloride as acid catalyst in an amount 0.1 to 10 molar equivalents, preferably 4 to 8 molar equivalents, most preferably 5 to 7 molar equivalents, of acid catalyst based on N-alkyl-1 -naphthylamine, preferably N-methyl-1 -naphthylamine.
- the instant process is a new method for preparing the pharmaceutical intermediate 4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1 -ylidene-methylamine from N-methyl-1 -naphthylamine as seen below:
- the crude oil is then dissolved in I50 ml of xylene and 200 mg of 5% palladium on charcoal catalyst is added. The reaction mixture is then heated to reflux for 16 hours. The palladium catalyst is then removed by filtration and the filtrate is concentrated to give 9 g of a crude oil which is purified by flash chromatography (silica gel, 2.5% ethyl acetate in hexane) to give 6 g of an oil in 60% yield.
- reaction mass is then added to 200 ml of chilled 2.5 N aqueous sodium hydroxide solution and stirred for 15 minutes. A total of 300 ml of ethyl acetate is used for extraction. All organic layers are combined and dried over anhydrous sodium sulfate and 3 g of activated carbon (DACRO G-60, 100 mesh). After 15 minutes, the mixture is filtered and the light yellow filtrate is concentrated under vacuum to give 7.3 g of a crude solid (96% yield). The crude solid is recrystallized with ether to give 4.7 g (isolated yield 61.8%) of a white solid, melting at 142- 144C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU38153/99A AU3815399A (en) | 1998-04-23 | 1999-04-12 | Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds |
| JP2000545846A JP2002513012A (en) | 1998-04-23 | 1999-04-12 | Method for producing tetralone imine for producing active pharmaceutical compound |
| EP99920645A EP1073645A2 (en) | 1998-04-23 | 1999-04-12 | Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds |
| IL13884999A IL138849A0 (en) | 1998-04-23 | 1999-04-12 | Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds |
| CA002328778A CA2328778A1 (en) | 1998-04-23 | 1999-04-12 | Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/065,272 US6054614A (en) | 1998-04-23 | 1998-04-23 | Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds |
| US09/065,272 | 1998-04-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1999055686A2 true WO1999055686A2 (en) | 1999-11-04 |
| WO1999055686A3 WO1999055686A3 (en) | 1999-12-16 |
Family
ID=22061546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1999/002456 Ceased WO1999055686A2 (en) | 1998-04-23 | 1999-04-12 | Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6054614A (en) |
| EP (1) | EP1073645A2 (en) |
| JP (1) | JP2002513012A (en) |
| CN (1) | CN1298383A (en) |
| AR (1) | AR016214A1 (en) |
| AU (1) | AU3815399A (en) |
| CA (1) | CA2328778A1 (en) |
| HU (1) | HUP0102643A3 (en) |
| IL (1) | IL138849A0 (en) |
| TR (1) | TR200003042T2 (en) |
| WO (1) | WO1999055686A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506940B1 (en) | 2000-01-04 | 2003-01-14 | Sun Pharmaceuticals Industries Ltd. | Process for converting stereoisomers of sertraline into sertraline |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4855500A (en) * | 1988-05-04 | 1989-08-08 | Pfizer Inc. | Process for preparing a ketimine |
| FR2632633B1 (en) * | 1988-06-08 | 1991-04-05 | Delalande Sa | PROCESS FOR THE PREPARATION OF 4-ARYL-1-TETRALONES |
-
1998
- 1998-04-23 US US09/065,272 patent/US6054614A/en not_active Expired - Fee Related
-
1999
- 1999-04-12 IL IL13884999A patent/IL138849A0/en unknown
- 1999-04-12 EP EP99920645A patent/EP1073645A2/en not_active Withdrawn
- 1999-04-12 JP JP2000545846A patent/JP2002513012A/en active Pending
- 1999-04-12 CN CN99805321A patent/CN1298383A/en active Pending
- 1999-04-12 CA CA002328778A patent/CA2328778A1/en not_active Abandoned
- 1999-04-12 HU HU0102643A patent/HUP0102643A3/en unknown
- 1999-04-12 AU AU38153/99A patent/AU3815399A/en not_active Abandoned
- 1999-04-12 TR TR2000/03042T patent/TR200003042T2/en unknown
- 1999-04-12 WO PCT/EP1999/002456 patent/WO1999055686A2/en not_active Ceased
- 1999-04-21 AR ARP990101846A patent/AR016214A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506940B1 (en) | 2000-01-04 | 2003-01-14 | Sun Pharmaceuticals Industries Ltd. | Process for converting stereoisomers of sertraline into sertraline |
Also Published As
| Publication number | Publication date |
|---|---|
| TR200003042T2 (en) | 2001-01-22 |
| WO1999055686A3 (en) | 1999-12-16 |
| AU3815399A (en) | 1999-11-16 |
| US6054614A (en) | 2000-04-25 |
| IL138849A0 (en) | 2001-10-31 |
| HUP0102643A3 (en) | 2003-12-29 |
| HUP0102643A2 (en) | 2002-05-29 |
| CA2328778A1 (en) | 1999-11-04 |
| JP2002513012A (en) | 2002-05-08 |
| CN1298383A (en) | 2001-06-06 |
| EP1073645A2 (en) | 2001-02-07 |
| AR016214A1 (en) | 2001-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ194714A (en) | Propenylamine derivatives and pharmaceutical compositions | |
| BG60333B2 (en) | Derivatives of cis-phenyl-1,2,3,4-tetrahydro-1-naphthylamine with anti-depressing effect | |
| EP1224159A1 (en) | Improved synthesis of racemic sertraline | |
| US20090131719A1 (en) | Process for the synthesis of (7-methoxy-1-naphthyl) acetonitrile and its application in the synthesis of agomelatine | |
| JPH0261458B2 (en) | ||
| US5296498A (en) | Guanidine compounds | |
| JP3000016B2 (en) | Preparation of optically active 2-amino-1,2,3,4-tetrahydronaphthalene and 3-aminochroman | |
| EP0946493B1 (en) | Process for preparing a naphtalenamine derivative | |
| CA1235430A (en) | Process for the preparation of basically substituted phenylacetonitriles | |
| US6054614A (en) | Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds | |
| JP2543983B2 (en) | Process for producing 4-disubstituted phenyl-1-tetralones | |
| US6262308B1 (en) | Process for the preparation of racemic sertraline | |
| HUP0302818A2 (en) | A process for the preparation of 2,2-dimethyl-5-(4-chlorobenzyl)cyclopentanone and an intermediate useful therefor | |
| US6548710B2 (en) | Process for preparing 1-indanones | |
| IL27887A (en) | 1,1-diphenyl-2-methyl-3-(benzylidene amino) propanols | |
| US6121492A (en) | Method for preparing 2-trifluoro-methoxy-aniline | |
| EP0925277A1 (en) | New intermediates for the preparation of verapamil derivates | |
| US6103938A (en) | Process for preparing 4-(substituted phenyl)-3,4-dihydro-2H-naphthalen-1-ones | |
| US5602282A (en) | Process for the preparation of 2-amino-2-arylethanols and novel intermediates | |
| FI56672C (en) | NYTT FOERFARANDE FOER FRAMSTAELLNING AV 2-AMINO-BENZAMINER | |
| US4215074A (en) | Process for preparing cis-bicyclooctylamines | |
| JPH09255643A (en) | New n-benzylbenzamide derivative | |
| GB1589776A (en) | Tetrabenzocycloheptenes | |
| GB2209748A (en) | Imidazolinyl derivatives of dihydronapthalene and tetrahydronapthalene | |
| WO2007119247A2 (en) | Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 99805321.X Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1999920645 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 138849 Country of ref document: IL |
|
| ENP | Entry into the national phase |
Ref document number: 2328778 Country of ref document: CA Ref document number: 2328778 Country of ref document: CA Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000/03042 Country of ref document: TR |
|
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2000/682/CHE Country of ref document: IN |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999920645 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1999920645 Country of ref document: EP |















